Mankind Pharma

What does Mankind Pharma do?

Mankind Pharma Ltd is a large-cap pharmaceutical company, incorporated in 1991, with net sales of ₹3,079 Cr and a net profit of ₹421 Cr for the quarter ending March 2025. It has a market cap of ₹97,159 Cr and a P/E ratio of 49.00.

Overview:<BR>Mankind Pharma Ltd is a large-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company and was converted to a Public Limited Company on July 14, 2005. The latest quarterly results report net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3,079 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 421 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 97,159 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 49.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.40<BR>- Return on Equity: 20.02%<BR>- Price to Book: 9.22<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Has Mankind Pharma declared dividend?

No Dividend History Available

Who are the peers of the Mankind Pharma?

Mankind Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Zydus Lifesciences, Lupin, Abbott India, and Aurobindo Pharma. Key metrics show excellent management and capital structures for most peers, with Divi's Lab leading in 1-year returns at 49.58%, while Mankind Pharma has a return of 23.90%.

Peers: The peers of Mankind Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Zydus Lifesci., Lupin, Abbott India, and Aurobindo Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Abbott India, and Aurobindo Pharma, while Average management risk is found at Lupin and Glenmark Pharma. Growth is excellent for Sun Pharma.Inds., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., and Lupin, while below average growth is noted for Divi's Lab., Torrent Pharma, Aurobindo Pharma, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Abbott India, and Aurobindo Pharma, while good capital structure is found at Torrent Pharma and Lupin, and Glenmark Pharma has a good capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 49.58%, while the peer with the lowest is Zydus Lifesci. at -18.37%. Mankind Pharma's 1-year return of 23.90% is higher than Zydus Lifesci. but lower than Divi's Lab. Additionally, the peers with negative six-month returns include Sun Pharma.Inds., Dr Reddy's Labs, Zydus Lifesci., and Lupin.

Who are in the management team of Mankind Pharma?

As of March 2023, the management team of Mankind Pharma includes Ramesh Chand Juneja (Chairman), Rajeev Juneja (Vice Chairman & Managing Director), Sheetal Arora (CEO), and several independent directors, along with other key executives. Each member contributes to the company's governance and management.

As of March 2023, the management team of Mankind Pharma includes the following individuals:<BR><BR>1. Ramesh Chand Juneja - Chairman & Wholetime Director<BR>2. Rajeev Juneja - Vice Chairman & Managing Director<BR>3. Sheetal Arora - Whole Time Director & CEO<BR>4. Tilokchand Punamchand Ostwal - Independent Director<BR>5. Pradeep Chugh - Company Secretary & Compliance Officer<BR>6. Bharat Anand - Independent Director<BR>7. Satish Kumar Sharma - Whole-time Director<BR>8. Vivek Kalra - Independent Director<BR>9. Vijaya Sampath - Independent Director<BR><BR>Each member plays a significant role in the governance and management of the company.

Who are the top shareholders of the Mankind Pharma?

The top shareholder of Mankind Pharma is the Ramesh Juneja Family Trust, holding 20.2%. Promoters own the majority, with institutional investors holding 20.59% combined, while individual investors own about 1.64%.

The top shareholders of Mankind Pharma include the Ramesh Juneja Family Trust, which holds the largest stake at 20.2%. The company is primarily owned by its promoters, with no pledged promoter holdings reported. Additionally, institutional investors are involved, with 32 mutual fund schemes holding a combined 7.67% and 554 foreign institutional investors (FIIs) holding 12.92%. The highest public shareholder is the SBI Large & Midcap Fund, which holds 1.58%. Individual investors collectively own about 1.64% of the company.

How big is Mankind Pharma?

As of 24th July, Mankind Pharma Ltd has a market capitalization of 107,927.00 Cr, with recent net sales of 12,248.09 Cr and a net profit of 1,990.96 Cr. The company reported shareholder's funds of 14,332.39 Cr and total assets of 27,651.64 Cr as of March 2025.

As of 24th July, Mankind Pharma Ltd has a market capitalization of 107,927.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Mankind Pharma reported Net Sales of 12,248.09 Cr and a Net Profit of 1,990.96 Cr.<BR><BR>For the reporting period of March 2025, the company had Shareholder's Funds amounting to 14,332.39 Cr and Total Assets of 27,651.64 Cr.

Is Mankind Pharma overvalued or undervalued?

As of October 13, 2025, Mankind Pharma is considered very expensive with a PE ratio of 53.30 and significant underperformance compared to peers and the Sensex, indicating it may be overvalued.

As of 13 October 2025, Mankind Pharma's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market perception. The company appears to be overvalued based on key financial ratios, including a PE ratio of 53.30, an EV to EBITDA of 33.50, and a Price to Book Value of 7.06. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Mankind Pharma's valuation stands out as particularly high; for instance, Sun Pharma has a PE ratio of 34.9, while Cipla is valued attractively with a PE of 23.43. The disparity in valuations raises concerns about Mankind's sustainability at these levels. Furthermore, the company's stock has underperformed against the Sensex, with a year-to-date return of -15.1% compared to the Sensex's gain of 5.36%. This underperformance further supports the conclusion that Mankind Pharma is currently overvalued.

When is the next results date for Mankind Pharma?

The next results date for Mankind Pharma is November 6, 2025.

The next results date for Mankind Pharma is scheduled for November 6, 2025.

How has been the historical performance of Mankind Pharma?

Mankind Pharma has shown consistent growth, with net sales increasing from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025, alongside rising profits and improved cash flow. Total assets surged from INR 6,323.62 crore to INR 27,651.64 crore during the same period.

Answer:<BR>The historical performance of Mankind Pharma shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Mankind Pharma's net sales have increased significantly from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025. This growth is reflected in the total operating income, which rose from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025. The total expenditure, excluding depreciation, also grew from INR 4,566.33 crore in March 2021 to INR 9,189.51 crore in March 2025, indicating rising operational costs. Operating profit (PBDIT) has shown a positive trend, climbing from INR 1,819.05 crore in March 2021 to INR 3,554.72 crore in March 2025. Profit before tax increased from INR 1,679.93 crore in March 2021 to INR 2,504.09 crore in March 2025, while profit after tax rose from INR 1,281.35 crore to INR 1,994.35 crore during the same period. The company's total assets surged from INR 6,323.62 crore in March 2021 to INR 27,651.64 crore in March 2025, with total liabilities also increasing from INR 6,323.62 crore to INR 8,483.03 crore. The cash flow from operating activities improved from INR 1,137 crore in March 2021 to INR 2,413 crore in March 2025, reflecting enhanced operational efficiency. Overall, Mankind Pharma has demonstrated robust growth in revenue and profitability, alongside a significant increase in assets and cash flow.

Is Mankind Pharma technically bullish or bearish?

As of December 1, 2025, the technical trend has shifted to a bearish stance, driven by bearish MACD and Bollinger Bands signals, despite a bullish weekly RSI, with the stock trading below its previous close and well off its 52-week high.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands on both weekly and monthly timeframes, and a bearish moving average on the daily timeframe. The weekly RSI is bullish, but this is overshadowed by the overall bearish trend in other indicators. The KST is mildly bearish, and there is no clear trend indicated by Dow Theory or OBV. Overall, the bearish sentiment is reinforced by the recent price action, with the stock trading below its previous close and significantly off its 52-week high.

Are Mankind Pharma Ltd latest results good or bad?

Mankind Pharma Ltd's latest results are concerning, showing an 11.52% year-on-year sales growth but a 3.52% sequential revenue decline, along with reduced operating margins and a significant drop in quarterly net profit. The high valuation relative to industry averages further complicates the outlook.

Mankind Pharma Ltd's latest results present a mixed picture, leaning towards the negative. While the company reported a year-on-year net sales growth of 11.52%, it experienced a sequential decline of 3.52% in revenue compared to the previous quarter. This marks the first quarterly revenue drop in recent periods, which raises concerns about its growth momentum.<BR><BR>Additionally, the operating margins have contracted from 27.67% to 25.77% year-on-year, indicating increasing pressure on profitability. The net profit of ₹408.75 crores reflects a 7.50% increase year-on-year but shows a significant decline of 20.09% compared to the previous quarter. This deterioration in profitability metrics, coupled with rising costs—particularly in employee expenses and interest—suggests that the company is facing operational challenges.<BR><BR>Moreover, Mankind Pharma's valuation at 50.88 times trailing earnings is substantially higher than the industry average of 32 times, making it increasingly difficult to justify given the flat financial trends and margin compression.<BR><BR>In summary, while there are some positive year-on-year growth figures, the sequential declines in revenue and profit, along with margin pressures and high valuation, indicate that the latest results are more concerning than favorable.

Should I buy, sell or hold Mankind Pharma Ltd?

Why is Mankind Pharma Ltd falling/rising?

As of 06-Feb, Mankind Pharma Ltd's stock price is at 2,055.00, reflecting a decline of 1.32%. The stock has significantly underperformed, with a year-to-date drop of 6.44% and a 17.20% decline over the past year, while investor interest has waned, contributing to a bearish outlook.

As of 06-Feb, Mankind Pharma Ltd's stock price is falling, currently at 2,055.00, which reflects a decrease of 27.55 or 1.32%. The stock has been underperforming significantly, with a decline of 3.29% over the past week and 8.33% over the past month. Year-to-date, it has dropped by 6.44%, and over the last year, it has seen a substantial decline of 17.20%, while the benchmark Sensex has increased by 7.07% during the same period.<BR><BR>Today's performance highlights a new 52-week low of Rs. 2029.35, indicating a downward trend. The stock has been losing for three consecutive days, with a total decline of 4.68% in that timeframe. Additionally, it has underperformed its sector by 0.52% today. The stock is trading below all its moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which is a bearish signal.<BR><BR>Investor participation has also decreased, with delivery volume falling by 41.62% compared to the 5-day average, suggesting reduced interest from investors. Despite some positive factors such as high management efficiency and strong growth in net sales and operating profit, the stock's valuation appears expensive compared to its peers, contributing to the negative sentiment. The company's flat results in December and declining profitability further exacerbate the situation, leading to a perception of poor performance both in the near and long term.

Which are the latest news on Mankind Pharma?